{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+50+or+100+mg&page=5",
    "query": {
      "intervention": "Placebo 50 or 100 mg",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 281,
    "total_pages": 29,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+50+or+100+mg&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+50+or+100+mg&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-11T13:28:49.818Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04505397",
      "title": "Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study of SKL24741 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "SKL24741",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SK Life Science, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 111,
      "start_date": "2020-02-13",
      "completion_date": "2022-10-27",
      "has_results": false,
      "last_update_posted_date": "2023-12-21",
      "last_synced_at": "2026-10-11T13:28:49.818Z",
      "location_count": 1,
      "location_summary": "West Bend, Wisconsin",
      "locations": [
        {
          "city": "West Bend",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04505397"
    },
    {
      "nct_id": "NCT04481685",
      "title": "A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "ATI-450",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2020-07-20",
      "completion_date": "2021-06-01",
      "has_results": true,
      "last_update_posted_date": "2025-06-04",
      "last_synced_at": "2026-10-11T13:28:49.818Z",
      "location_count": 1,
      "location_summary": "Kansas City, Kansas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04481685"
    },
    {
      "nct_id": "NCT03973489",
      "title": "Effects of Genotype on Resting State Connectivity During Methamphetamine Administration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Methamphetamine-dependence"
      ],
      "interventions": [
        {
          "name": "Magnetic resonance imaging (MRI)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Methamphetamine Hydrochloride Tablets",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 69,
      "start_date": "2019-08-16",
      "completion_date": "2023-03-31",
      "has_results": true,
      "last_update_posted_date": "2024-11-15",
      "last_synced_at": "2026-10-11T13:28:49.818Z",
      "location_count": 2,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03973489"
    },
    {
      "nct_id": "NCT00653185",
      "title": "Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "SYR-472",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 369,
      "start_date": "2007-05",
      "completion_date": "2008-03",
      "has_results": false,
      "last_update_posted_date": "2016-06-22",
      "last_synced_at": "2026-10-11T13:28:49.818Z",
      "location_count": 51,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 48 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Pell City",
          "state": "Alabama"
        },
        {
          "city": "Tallassee",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00653185"
    },
    {
      "nct_id": "NCT00979953",
      "title": "Efficacy and Safety Study Evaluating ADL5859 and ADL5747 in Participants With Pain Due to Osteoarthritis of the Knee",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteoarthritis of the Knee"
      ],
      "interventions": [
        {
          "name": "ADL5859",
          "type": "DRUG"
        },
        {
          "name": "ADL5747",
          "type": "DRUG"
        },
        {
          "name": "Oxycodone CR",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 408,
      "start_date": "2009-10",
      "completion_date": "2010-06",
      "has_results": true,
      "last_update_posted_date": "2015-08-14",
      "last_synced_at": "2026-10-11T13:28:49.818Z",
      "location_count": 11,
      "location_summary": "Daytona Beach, Florida • Stockbridge, Georgia • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Stockbridge",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Gurnee",
          "state": "Illinois"
        },
        {
          "city": "Salisbury",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00979953"
    },
    {
      "nct_id": "NCT02169583",
      "title": "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infections, Respiratory Tract"
      ],
      "interventions": [
        {
          "name": "GSK1325756 Solution",
          "type": "DRUG"
        },
        {
          "name": "GSK1325756 Solution Matching Placebo",
          "type": "DRUG"
        },
        {
          "name": "GSK1325756 Tablet",
          "type": "DRUG"
        },
        {
          "name": "GSK1325756 Tablet Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2014-06-12",
      "completion_date": "2014-08-28",
      "has_results": false,
      "last_update_posted_date": "2017-05-15",
      "last_synced_at": "2026-10-11T13:28:49.818Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02169583"
    },
    {
      "nct_id": "NCT01834274",
      "title": "Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Fasiglifam (TAK-875)",
          "type": "DRUG"
        },
        {
          "name": "Fasiglifam (TAK-875) Placebo",
          "type": "DRUG"
        },
        {
          "name": "Sitagliptin",
          "type": "DRUG"
        },
        {
          "name": "Sitagliptin Placebo",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 96,
      "start_date": "2013-06",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2015-09-28",
      "last_synced_at": "2026-10-11T13:28:49.818Z",
      "location_count": 44,
      "location_summary": "Huntsville, Alabama • Chandler, Arizona • Glendale, Arizona + 41 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01834274"
    },
    {
      "nct_id": "NCT03701555",
      "title": "A Study of PVP001, PVP002, and PVP003 in Healthy Adults and PVP001 and PVP002 in Adults With Celiac Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Digestive System Disease"
      ],
      "interventions": [
        {
          "name": "PvP001 placebo",
          "type": "OTHER"
        },
        {
          "name": "PvP001 100 mg",
          "type": "DRUG"
        },
        {
          "name": "PvP001 300 mg",
          "type": "DRUG"
        },
        {
          "name": "PvP001 900 mg",
          "type": "DRUG"
        },
        {
          "name": "Maximum Feasible Dose (MFD) of PvP002",
          "type": "DRUG"
        },
        {
          "name": "Maximum Tolerated Dose (MTD) of PvP001",
          "type": "DRUG"
        },
        {
          "name": "MTD of PvP001 following 7 days of PPI treatment",
          "type": "DRUG"
        },
        {
          "name": "PvP002 placebo",
          "type": "OTHER"
        },
        {
          "name": "PvP001 600 mg",
          "type": "DRUG"
        },
        {
          "name": "PvP003 placebo",
          "type": "DRUG"
        },
        {
          "name": "PvP003",
          "type": "DRUG"
        },
        {
          "name": "PvP003 150 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Millennium Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 139,
      "start_date": "2018-06-19",
      "completion_date": "2021-07-02",
      "has_results": true,
      "last_update_posted_date": "2023-04-04",
      "last_synced_at": "2026-10-11T13:28:49.818Z",
      "location_count": 1,
      "location_summary": "Anaheim, California",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03701555"
    },
    {
      "nct_id": "NCT03082235",
      "title": "Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "E6742",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 72,
      "start_date": "2017-03-03",
      "completion_date": "2017-10-11",
      "has_results": false,
      "last_update_posted_date": "2018-09-07",
      "last_synced_at": "2026-10-11T13:28:49.818Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03082235"
    },
    {
      "nct_id": "NCT04310579",
      "title": "Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hypercapnia",
        "Ventilatory Depression"
      ],
      "interventions": [
        {
          "name": "Oxycodone and Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Oxycodone, Paroxetine, and Quetiapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Food and Drug Administration (FDA)",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 55,
      "start_date": "2020-06-15",
      "completion_date": "2021-05-25",
      "has_results": true,
      "last_update_posted_date": "2024-05-21",
      "last_synced_at": "2026-10-11T13:28:49.818Z",
      "location_count": 1,
      "location_summary": "West Bend, Wisconsin",
      "locations": [
        {
          "city": "West Bend",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04310579"
    }
  ]
}